Veru Inc.

Contributing Author

Recent Articles by Veru Inc.

May-28	Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone VERU GlobeNewswire
May-08	Veru Participates in a Virtual Investor KOL Connect Segment VERU GlobeNewswire
May-08	Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress VERU GlobeNewswire
May-01	Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 VERU GlobeNewswire